Fig. 5.

The angiotensin II type 1 (ATII) receptor inhibitor losartan (5 μmol) significantly (*p < 0.05) reduces the release of ³H-norepinephrine (³H-NE) in response to field stimulation (5 Hz) in non-supplemented SHRs (n = 5) to the same levels observed in SHRs treated with pravastatin (n = 5) (A). Exogenous ATII (20 nmol/l) is able to significantly increase ³H-NE release (*p < 0.05) in both non-supplemented (n = 6) and pravastatin treated (n = 8) SHRs, an effect that can be reversed by losartan (B).